ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
What does it do?
ACADIA Pharmaceuticals makes medicines for serious brain disorders. Their biggest product, NUPLAZID, treats hallucinations and delusions in people with Parkinson's disease — imagine a patient seeing things that aren't there, and this drug helps stop that. Their second drug, DAYBUE, treats Rett syndrome, a rare genetic disorder that affects brain development mostly in young girls, causing them to lose the ability to speak and use their hands. These are conditions with very few treatment options, which is exactly the kind of gap ACADIA tries to fill.
ACADIA is one of the rare small biotechs that has crossed into actual profitability — it made $400 million in net income on $1.1 billion in revenue, which is unusual for a company this size in this industry. Most biotechs burn cash for years; ACADIA is already generating real profits, making it a different kind of healthcare bet. With two approved drugs and a pipeline of potential new treatments, it sits at an interesting crossroads between an established business and a growth story.
How does it make money?
ACADIA makes money by selling two FDA-approved prescription drugs directly to patients through doctors and hospitals in North America. NUPLAZID is the workhorse, having been on the market since 2016 and generating the bulk of that $1.1 billion in annual revenue. DAYBUE is the newer product, approved in 2023 for Rett syndrome, and is still in its early commercial phase — meaning sales are growing but haven't yet hit their full potential. Revenue grew from $1.0 billion to $1.1 billion year-over-year, a roughly 10% increase, driven largely by DAYBUE ramping up.
Why do investors care?
The growth story here is really about DAYBUE. Rett syndrome affects roughly 6,000 to 9,000 girls in the US, and DAYBUE is the only approved treatment — that kind of monopoly on a rare disease drug can command very high prices and loyal prescribers. If DAYBUE continues to be adopted by doctors and expands internationally, it could meaningfully grow revenue beyond what NUPLAZID alone could deliver. The risk is that rare disease drugs can plateau quickly if the eligible patient pool is small, so investors are watching how many new patients start treatment each quarter.
Deep Dive
MemberA full investor briefing on ACADIA Pharmaceuticals Inc. — history, leadership, risks, and outlook.